Naluzotan

DB05562InvestigationalSmall molecule

Investigated for use/treatment in anxiety disorders and depression.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 1A
Curator reviewed
Primary indication: Investigated for use/treatment in anxiety disorders and depression.Curator reviewed
Formula / weight: C₂₃H₃₈N₄O₃S · 450.64 g/mol (avg)
Code names: PRX-00023

Resolves to

Compound

Structure

InChIKeySPWZXWDPAWDKQE-UHFFFAOYSA-NSMILESCC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,068Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Naluzotan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.